Namodenoson - (CF102-222PC)

Aug. 12, 2026: Can-Fite BioPharma Ltd. (NYSE: CANF; TASE: CANF) provided a regulatory and clinical update on two Phase III programs. Namodenoson, an oral A3 adenosine receptor agonist, is in a pivotal Phase III trial for advanced hepatocellular carcinoma in patients with Child-Pugh B7 cirrhosis. The company said the HCC study is being conducted under FDA and EMA guidance and could support U.S. and European marketing applications if predefined efficacy and safety endpoints are met. Namodenoson also holds FDA Fast Track designation and U.S./European Orphan Drug designations, including Fast Track as a second-line HCC treatment.

Piclidenoson, also an oral A3 adenosine receptor agonist, is in Phase III development for moderate-to-severe plaque psoriasis. The company also stated that Piclidenoson recently reported topline results from a Phase 3 psoriasis trial and has commenced a pivotal Phase 3 trial, though no efficacy details were provided.

Additional pipeline items mentioned: Namodenoson is also in Phase 2b for MASH and Phase 2a for pancreatic cancer; CF602 has shown efficacy in erectile dysfunction.